Purple Biotech (PPBT) Cash from Operations (2017 - 2026)

Purple Biotech (PPBT) has 10 years of Cash from Operations data on file, last reported at 3121000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 57.79% year-over-year to 3121000.0 in Q1 2026; TTM through Mar 2026 was 6799000.0, a 39.63% increase from a year earlier, with the FY2025 full-year figure at 5656000.0, up 60.63% from the prior year.
• Cash from Operations for Q1 2026 stood at 3121000.0, down from 1067000.0 in the prior quarter.
• Over the last five years, Cash from Operations for PPBT reached as high as 1067000.0 in Q3 2025 and fell as low as 6064000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 3517882.35 across 5 years, with a median of 3656000.0 in 2023.
• Across the five-year window, Cash from Operations jumped 67.62% in 2025 and sank 57.79% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 4214000.0 in 2022, then dropped by 18.22% to 4982000.0 in 2023, then soared by 59.57% to 2014000.0 in 2024, then soared by 47.02% to 1067000.0 in 2025, then sank by 192.5% to 3121000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 3121000.0 in Q1 2026, 1067000.0 in Q4 2025, and 1067000.0 in Q3 2025.